| dbo:abstract
|
- N-Ethylhexedron (auch bekannt als α-Etilaminokaprofenon, Hexen oder NEH) ist eine chemische Verbindung, die 2011 synthetisiert wurde und 2015 erstmals auf dem sogenannten „Research Chemical-Markt“ (Markt für neue psychoaktive Substanzen) auftauchte. Das Stimulans gehört zur Stoffgruppe der Cathinone. (de)
- N-Ethylhexedrone (also known as α-ethylaminocaprophenone, N-ethylnorhexedrone, hexen, and NEH) is a stimulant of the cathinone class that acts as a norepinephrine–dopamine reuptake inhibitor (NDRI) with IC50 values of 0.0978 and 0.0467 μM, respectively. N-Ethylhexedrone was first mentioned in a series of patents by Boehringer Ingelheim in the 1960s which led to the development of the better-known drug methylenedioxypyrovalerone (MDPV). Since the mid-2010s, N-ethylhexedrone has been sold online as a designer drug. In 2018, N-ethylhexedrone was the second most common drug of the cathinone class to be identified in Drug Enforcement Administration seizures. N-Ethylhexedrone was first synthesized by Boehringer Ingelheim in 1964. It appears to have emerged on the online research chemical market in late 2015. It is an example of a novel psychoactive substance specifically chosen to mimic the features of prohibited substances and bypass drug laws. It is one of a number of substances collectively referred to as "bath salts". User reports characterize N-ethylhexedrone as having euphoric stimulant effects comparable to those of crack-cocaine and α-PVP-type compounds, particularly when they are insufflated or vaporized. Like other substituted cathinones, N-ethylhexedrone has gained notoriety for its association with and addictive behaviors when abused. (en)
|
| dbo:casNumber
| |
| dbo:fdaUniiCode
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 22734 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:c
| |
| dbp:casNumber
|
- 18410 (xsd:integer)
- 802857 (xsd:integer)
|
| dbp:chemspiderid
| |
| dbp:drugName
| |
| dbp:h
| |
| dbp:index2Label
| |
| dbp:iupacName
| |
| dbp:legalCa
| |
| dbp:legalDe
| |
| dbp:legalStatus
|
- Illegal in Japan and a controlled substance in Sweden (en)
|
| dbp:legalUk
| |
| dbp:legalUn
| |
| dbp:legalUs
| |
| dbp:metabolism
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pubchem
| |
| dbp:smiles
| |
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- CWNKMHIETKEBCA-UHFFFAOYSA-N (en)
|
| dbp:unii
|
- BH93PZ33WU (en)
- TAX3KSX6GY (en)
|
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- N-Ethylhexedron (auch bekannt als α-Etilaminokaprofenon, Hexen oder NEH) ist eine chemische Verbindung, die 2011 synthetisiert wurde und 2015 erstmals auf dem sogenannten „Research Chemical-Markt“ (Markt für neue psychoaktive Substanzen) auftauchte. Das Stimulans gehört zur Stoffgruppe der Cathinone. (de)
- N-Ethylhexedrone (also known as α-ethylaminocaprophenone, N-ethylnorhexedrone, hexen, and NEH) is a stimulant of the cathinone class that acts as a norepinephrine–dopamine reuptake inhibitor (NDRI) with IC50 values of 0.0978 and 0.0467 μM, respectively. N-Ethylhexedrone was first mentioned in a series of patents by Boehringer Ingelheim in the 1960s which led to the development of the better-known drug methylenedioxypyrovalerone (MDPV). Since the mid-2010s, N-ethylhexedrone has been sold online as a designer drug. In 2018, N-ethylhexedrone was the second most common drug of the cathinone class to be identified in Drug Enforcement Administration seizures. (en)
|
| rdfs:label
|
- N-Ethylhexedron (de)
- N-Ethylhexedrone (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| foaf:name
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
